Lakewood-Amedex Biotherapeutics Inc (LABT) Stock AnalysisLABTStock AnalysisLakewood-Amedex Biotherapeutics Inc

Lakewood-amedex Biotherapeutics Inc is a pharmaceutical company. The Company is focused on addressing unmet needs in the treatment of serious infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains like MRSA, NDM-1, and many others. The Company is engaged in development of its Bisphosphocin class of antimicrobial agents. The Company is exploring additional local drug delivery applications, including complicated urinary tract infections (CAUTI) and pulmonary infections. The Company has a portfolio of compounds that are being profiled for indications such as infected diabetic foot ulcer, urinary tract infections, and pulmonary infections. It operates in the Healthcare sector.

Lakewood-Amedex Biotherapeutics Inc. (LABT) appears to be a good buy right now due to its recent surge of over 80% following positive updates on its antimicrobial drug candidate Nu-3, which aligns with market needs against antibiotic resistance. The stock is currently priced at $2.30, significantly below its 200-day simple moving average of $11.221, indicating potential for recovery. However, the company has reported a negative EPS of -2.66 in the latest quarter, which poses a risk to investors.